We have read with great interests the recent article on the low seroprevalence (1.6 %) of SARS-CoV-2 positive healthcare workers (HCWs) of the University Hospital Essen, Germany, during the last epidemic peak in Europe \[[@bib0005]\]. We report herein on our experience in Paris university hospital, France, showing much higher prevalence of SARS-CoV-2 seropositivity in HCWs and the need to use a confirmation strategy for equivocal results.

The serological diagnosis of on-going or past SARS-CoV-2 infection in HCWs has been promoted by the *Assistance Publique-Hôpitaux de Paris,* France, to make the diagnosis of past infection which may entitle the patient to receive care or compensation as an occupational disease.

In April 2020, the Abbott SARS-CoV-2 IgG assay (Des Plaines, IL, USA), targeting SARS-CoV-2 nucleoprotein, received the CE-IVD label and was installed on our automated Abbott Architect™ i2000 platform at *Hôpital Européen Georges Pompidou*, Paris, as described \[[@bib0010]\]. At same time, we had the opportunity to evaluate the CE-IVD ACCESS SARS-CoV-2 IgG assay (Beckman Coulter, Inc., Brea, CA, USA), targeting SARS-CoV-2 spike surface protein, with the high-throughput UniCel DxI 800 Access Immunoassay System (Beckman Coulter), to increase hospital productivity in SARS-CoV-2 IgG serology testing. The analytical performance of the Beckman Coulter assay was assessed using serum samples obtained from inpatients with COVID-19 confirmed by molecular diagnosis at least 4 weeks ago (n = 104) and from patients randomly selected for whom serum samples were collected before the COVID-19 outbreak (n = 56). The ACCESS SARS-CoV-2 IgG assay showed sensitivity of 93 % (95% CI: 86 %--97 %), and specificity of 100 % (95 % CI: 93 %--100 %), demonstrating high analytical performances allowing convenient management of suspected on-going and past-infections, similar to the Abbott SARS-CoV-2 IgG assay.

In France, the end of confinement took place on May 11th, 2020. The virology laboratory of *Hôpital Européen Georges Pompidou* was then called upon to test all hospital staff exposed to the virus during the epidemic peak. From May 2nd to 26th June 2020, we tested with the Abbott SARS-CoV-2 IgG assay 3569 staff HCWs (female, 74.8 %; median age, 39.6 years) in the hospital department of occupational medicine, on a voluntary basis. SARS-CoV-2 IgG antibodies were detected in 423 (11.9%) HCWs. The distribution of index values of Abbott SARS-CoV-2 IgG-negative HCWs is depicted in [Fig. 1](#fig0005){ref-type="fig"} **A**. A total of 90 (2.5 %) HCWs with equivocal Abbott index values were further retested with Beckman Coulter IgG assay: 70 were SARS-CoV-2 IgG-negative, 6 showed equivocal results, and 14 (15.5 %; 0.4 % of HCWs) were SARS-CoV-2 IgG-positive ([Fig. 1](#fig0005){ref-type="fig"} **B**).Fig. 1**A.** Distribution of Abbott SARS-CoV-2 IgG-negative index values from 3569 health care workers. The instructions for use of the Abbott assay indicate an index value threshold for positivity at 1.40 arbitrary units (au), without grey zone. We defined an equivocal zone for Abbott SARS-CoV-2 IgG assay between the mean of Abbott SARS-CoV-2 IgG-negative index values + 2 standard deviations (SD) \[0.380 = 0.070 + 2 × 0.155 au\] and the Abbott positivity threshold. Left dotted line indicates the mean of the distribution, the middle dotted line inferior limit of the Abbott equivocal zone and the solid straight line the positivity threshold given by the manufacturer. **B.** SARS-CoV-2 IgG detection with ACCESS SARS-CoV-2 IgG assay of 98 health care workers with Abbott index values within the equivocal zone for Abbott SARS-CoV-2 IgG assay, between 0.38 and 1.40 au, expressed as "Beckman index values" au. The positivity threshold of the ACCESS SARS-CoV-2 IgG assay and the grey zone of the Beckman test between 0.8 and 1.0 given by the manufacturer are indicated.Fig. 1

The combination strategy of two SARS-CoV-2 IgG assays having different targets in series with final interpretation given by the second test was used to address the issues of HCWs with equivocal results by the first test. In our series, such strategy made possible to recover 14 sera having index values in the Abbott equivocal zone. This strategy is cost effective as only a limited number of equivocal sera are retested, allowing to increase the number of HCWs eligible to possible compensation with a positive serology. Taken together, our observations provide the rational basis for confirmatory testing by another SARS-CoV-2 IgG assay in case of doubtful initial screening in occupational medicine.
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